Article
Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies
1 Jan 2021
Abstract excerpt
Based on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer patients for whom no other options exist. ACT of TIL, peripheral blood or gene-engineered peripheral blood lymphocytes (PBLs) targeting neoantigens is a highly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
